Results 41 to 50 of about 234,795 (273)

Targeting Cannabinoid 1 Receptor in Macrophages Alleviates Psoriatic Skin Inflammation Through the AUF1–NLRP3 Axis

Advanced Science, EarlyView.
Macrophage CB1R emerges as a key driver of psoriatic inflammation by suppressing AUF1‐mediated post‐transcriptional control of NLRP3. CB1R inhibition restores AUF1‐dependent NLRP3 mRNA decay, restrains inflammasome activation, and alleviates psoriasis‐like inflammation.
Hongseo Choi, Sukyoung Han, Jinho Kim, Ji Hye Han, Eunsu Kim, Yeonjeong Heo, Minju Lee, Jooyoung Lee, Heerim You, Soyoun Lee, Su‐Hee Han, Ilrok Yoon, Sung Anjeon, Hyerim Kang, Seungyeon Ryu, Hyun‐Ji Park, Eunha Kim, Chul Hwan Bang, Ji Hyun Lee, Josephine M. Egan, Jung‐Woong Kim, Eun Kyung Lee, Wook Kim   +22 more
wiley   +1 more source

Immunomodulatory effects of Zingiber officinale Roscoe var. rubrum (Halia Bara) on inflammatory responses relevant to psoriasis [PDF]

, 2012
PhDPsoriasis is a chronic autoimmune skin disease characterised by hyperplasia of epidermal keratinocytes and the accumulation of activated immune cells at sites of the disease.
Nordin, Nurul Izza
core   +2 more sources

A modern approach to the treatment of plaque psoriasis

Acta Pharmaceutica, 2019
Abstract Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the population suffer from psoriasis. Distribution of the disease is bimodal, with the first peak at the age of 20–30, and the second at the age of 50–60.
Ledić Drvar, Daniela, Vlahinić, Tomislav, Maleš, Željan, Turčić, Petra, Čeović, Romana   +4 more
openaire   +4 more sources

Biologics in Plaque Psoriasis

Canadian Journal of Health Technologies, 2021
Health Canada has approved 11 biologics for the treatment of adults with moderate-to-severe plaque psoriasis (PsO). These biologics can be divided into 2 groups based on mechanisms of action and market authorization dates: Old-generation biologics (5): include anti–tumour necrosis factor (TNF) agents (etanercept, adalimumab ...
Peter Dyrda, Sirjana Pant
openaire   +2 more sources

Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases

SAGE Open Medical Case Reports
Palmoplantar plaque psoriasis is more resistant to therapy compared to other phenotypes of psoriasis. To our knowledge, there are no reports of the efficacy of Janus kinase (JAK) inhibitors for palmoplantar plaque psoriasis.
Bohmyi Choi, Heidi Oi-Yee Li, Steven J Glassman   +2 more
doaj   +1 more source

Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study

Annals of Medicine
Background Real-world data on health-related quality of life (HRQoL) in generalized pustular psoriasis (GPP) are scarce and studies have been restricted in terms of instruments used for assessments.Objective To assess generic and dermatology-specific ...
Jenny M. Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf   +2 more
doaj   +1 more source

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis

Clinical, Cosmetic and Investigational Dermatology, 2022
Small molecule medications like apremilast are emerging as promising options for patients with psoriasis and other inflammatory conditions. Apremilast was approved by the Food and Drug Administration in 2014 for the management of both psoriasis and psoriatic arthritis. Apremilast inhibits phosphodiesterase-4, which increases the intracellular levels of
Gao,Jia C, Wu,Albert G, Contento,Marissa N, Maher,Jacqueline M, Cline,Abigail   +4 more
openaire   +4 more sources

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Severe plaque psoriasis with coexisting cicatricial alopecia treated with adalimumab – case report

, 2014
Introduction. Tumor necrosis factor α (TNF-α) inhibitors are used in the management of many immune-mediated diseases, including the treatment of severe plaque psoriasis. Lichen planopilaris is an inflammatory dermatosis, which typically affects women at
Aldona Pietrzak, Michał Adamczyk, Małgorzata Michalska-Jakubus, Dorota Krasowska   +3 more
core   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

Arthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen, Sanjaykumar Boddul, Zhaojun Li, Zsolt Kasza, Marlene Schülein, Bruno Raposo, Karine Chemin, Per‐Johan Jakobsson, Alexander Espinosa, Lars Klareskog, Fredrik Wermeling   +10 more
wiley   +1 more source